Harrison, Stephen A.

Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review

Ajmera, V. H., Terrault, N. A., & Harrison, S. A. (2017) · Hepatology

Alcohol Consumption and Health EffectsLiver Disease Diagnosis and Treatment

Cited by 137

Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis

Sanyal, A. J., Ratziu, V., Loomba, R., Anstee, Q. M., Kowdley, K. V., Rinella, M. E., Sheikh, M. Y., Trotter, J. F., Knapple, W., Lawitz, E. J., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 137

Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: a randomized, double-blind, placebo controlled trial

Navarro, V. J., Belle, S. H., D’Amato, M., Adfhal, N., Brunt, E. M., Fried, M. W., Reddy, K. R., Wahed, A. S., Harrison, S., & on behalf of the Silymarin in NASH and C Hepatitis (SyNCH) Study Group (2019) · PLoS ONE

Silymarin and Mushroom PoisoningLiver Disease Diagnosis and Treatment

Cited by 125

The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis

Younossi, Z. M., Anstee, Q. M., Wai-Sun Wong, V., Trauner, M., Lawitz, E. J., Harrison, S. A., Camargo, M., Kersey, K., Subramanian, G. M., Myers, R. P., et al. (2021) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 118

Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience

Perumpail, R. B., Wong, R. J., Ahmed, A., & Harrison, S. A. (2015) · Digestive Diseases and Sciences

Hepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and Treatment

Cited by 111

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis

Loomba, R., Huang, D. Q., Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Ding, D., Ma, L., Jia, C., Billin, A., et al. (2023) · Gut

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 110

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis

Harrison, S. A., Ruane, P. J., Freilich, B., Neff, G., Patil, R., Behling, C., Hu, C., Shringarpure, R., de Temple, B., Fong, E., et al. (2023) · JHEP Reports

Liver Disease Diagnosis and TreatmentHepatitis C virus research

Cited by 110

Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: A case series

Kenny, P. R., Brady, D. E., Torres, D. M., Ragozzino, L., Chalasani, N., & Harrison, S. A. (2010) · American Journal of Gastroenterology

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 106

PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH

Gastaldelli, A., Sabatini, S., Carli, F., Gaggini, M., Bril, F., Belfort‐DeAguiar, R., Positano, V., Barb, D., Kadiyala, S., Harrison, S., et al. (2021) · Liver International

Liver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors

Cited by 101

Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH

Ratziu, V., Harrison, S. A., Loustaud-Ratti, V., Bureau, C., Lawitz, E., Abdelmalek, M., Alkhouri, N., Francque, S., Girma, H., Darteil, R., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 101

A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis

Mak, L.-Y., Gane, E., Schwabe, C., Yoon, K. T., Heo, J., Scott, R., Lee, J.-H., Lee, J. I., Kweon, Y. O., Weltman, M., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentRNA Interference and Gene Delivery

Cited by 98

Evaluation of PXL065–deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1)

Harrison, S. A., Thang, C., Bolze, S., Dewitt, S., Hallakou-Bozec, S., Dubourg, J., Bedossa, P., Cusi, K., Ratziu, V., Grouin, J.-M., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and Protection

Cited by 96

Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis

Chang, D., Truong, E., Mena, E. A., Pacheco, F., Wong, M., Guindi, M., Todo, T. T., Noureddin, N., Ayoub, W., Yang, J. D., et al. (2023) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 92

The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH

Loomba, R., Ling, L., Dinh, D. M., DePaoli, A. M., Lieu, H. D., Harrison, S. A., & Sanyal, A. J. (2021) · Hepatology

Gut microbiota and healthLiver Disease Diagnosis and Treatment

Cited by 88

Physical activity, measured objectively, is associated with lower mortality in patients with nonalcoholic fatty liver disease

Kim, D., Murag, S., Cholankeril, G., Cheung, A., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2021) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentPhysical Activity and Health

Cited by 86

Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study

Harrison, S. A., Manghi, F. P., Smith, W. B., Alpenidze, D., Aizenberg, D., Klarenbeek, N., Chen, C.-Y., Zuckerman, E., Ravussin, E., Charatcharoenwitthaya, P., et al. (2022) · Nature Medicine

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 75

NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned

Rasmussen, D. G. K., Anstee, Q. M., Torstenson, R., Golding, B., Patterson, S. D., Brass, C., Thakker, P., Harrison, S., Billin, A. N., Schuppan, D., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentStatistical Methods in Clinical Trials

Cited by 41

Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

Mayo, M. J., Vierling, J. M., Bowlus, C. L., Levy, C., Hirschfield, G. M., Neff, G. W., Galambos, M. R., Gordon, S. C., Borg, B. B., Harrison, S. A., et al. (2024) · Alimentary Pharmacology & Therapeutics

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 39

Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials

Wong, V. W.-S., Tak, W. Y., Goh, G. B. B., Cheng, P.-N., Lawitz, E. J., Younossi, Z. M., Vuppalanchi, R., Younes, Z., Alkhouri, N., Wang, L., et al. (2023) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 31

Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial

Harrison, S., Tomah, S., Suschak, J., Roberts, S., Yang, J., He, L., Georges, B., Rodwell-Green, L., Brown, R., Harris, M. S., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 4

OS-124 Identification and validation of pre-identified morphological baseline features for prediction of fibrosis progression in MAESTRO-NASH

Harrison, S. A., Taub, R., Labriola, D., Zhang, H., Chng, E., Ren, Y., Tai, D., & Schattenberg, J. M. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentRadiomics and Machine Learning in Medical Imaging

Cited by 3

Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis

Harrison, S. A., Neff, G., Guy, C., Bashir, M., Paredes, A., Frias, J., Younes, Z. H., Trotter, J. F., Gunn, N. T., Moussa, S., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 1

TOP-289 Artificial intelligence-based measurement of non-alcoholic steatohepatitis is an accurate tool for clinical trial enrollment and end point assessment

Pulaski, H., Hou, H., Resnick, M., Harrison, S. A., Sanyal, A. J., Ratziu, V., Burt, A., Bedossa, P., Montalto, M., & Wack, K. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentArtificial Intelligence in Healthcare and Education

Cited by 1

THU-242 Comparison ofmachine learning model (MASML), VCTE, and FIB-4 scores for predicting the presence of MASLD in a large cohort of patients in the U.S. using the NHANES database

Noureddin, M., Rubinsztain, J., Taub, K., Chang, D. Y., Harrison, S. A., & Alkhouri, N. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1